Cargando…
Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer
The distinct hormone molecules and receptors, such as follicle-stimulating hormone receptor (FSHR) in ovarian cancer, provide opportunities for more precisely targeted therapy. We previously developed FSHR-mediated nanoparticles and found that FSH peptides on the surface of nanoparticles improved th...
Autores principales: | Hong, Shan-Shan, Zhang, Ming-Xing, Zhang, Meng, Yu, Yi, Chen, Jun, Zhang, Xiao-Yan, Xu, Cong-Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058603/ https://www.ncbi.nlm.nih.gov/pubmed/29461120 http://dx.doi.org/10.1080/10717544.2018.1440667 |
Ejemplares similares
-
Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo
por: Zhang, Ming-Xing, et al.
Publicado: (2018) -
Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate
por: WANG, WEI-SHAN, et al.
Publicado: (2014) -
Silencing Human Rb2/p130 with shRNA
por: Leucci, Eleonora, et al.
Publicado: (2007) -
ShRNA-mediated silencing of hTERT promote apoptosis and senescence in human ovarian cancer cells
por: Su, Chen, et al.
Publicado: (2019) -
Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro
por: Dong, Pei-Xin, et al.
Publicado: (2008)